Skip to content

MoonLake Immunotherapeutics MLTX Short-Term Investments

Short-Term Investments at other companies

Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
$107.12M+347%
AnaptysBio, Inc. logo
AnaptysBio, Inc.ANAB
$37.99M-84.3%
Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$276.8M+21.8%
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$419.03M+133%
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
$506.84M+35.8%
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT
$189.24M+30.5%

Other financials

Income statement

See full
Operating income-$70.0M-47.5%
Net income-$69.7M-74.5%
EPS (diluted)-$0.98-55.6%

Balance sheet

See full
Cash & equivalents$298.5M+9.9%
Total debt$100.8M+33.3%
Total equity$254.0M-37.7%
Total assets$400.4M-21.7%

Cash flow

See full
Operating cash flow-$66.3M-73.8%
CapEx--100%
Free cash flow-$66.3M-73.6%

Valuation

See full
Market cap$1.49B-45.9%
Enterprise value$1.29B-50.0%

Returns & leverage

See full
Return on equity-77.7%-221pp
Debt / equity0.4×+0.2×
Current ratio8.6×-12.5×

Where this comes from

Reported directly by MoonLake Immunotherapeutics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent.

The official record: MoonLake Immunotherapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about MoonLake Immunotherapeutics's short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is MoonLake Immunotherapeutics's short-term investments?
MoonLake Immunotherapeutics (MLTX) reported short-term investments of $59.43M in Q1 2026.
How has MoonLake Immunotherapeutics's short-term investments changed year-over-year?
MoonLake Immunotherapeutics's short-term investments decreased by 71.5% year-over-year, from $208.56M to $59.43M.
What does short-term investments mean?
Marketable securities and other investments with maturities between three months and one year, providing yield above cash while maintaining liquidity.